Product pipeline
We have biosimilars products continuously under development to help improve healthcare accessibility worldwide.
What are biosimilars?
Biosimilars have no clinical differentiation from existing, approved biologics, with equivalent efficacy and safety.
The development and manufacture of biosimilars is a complex and challenging process. We have invested in our biosimilar capabilities with our advanced pipeline and EnzeneXTM continuous bioprocess manufacturing, allowing us to develop, manufacture and launch a range of biosimilar products.
Demand for biosimilars is increasing because of:
- Patent expirations: Blockbuster biologics patents are expiring, paving the way for biosimilar manufacturers to develop and commercialize products
- Cost-effectiveness: Biosimilars offer a more affordable alternative to biologics while maintaining comparable efficacy and safety
- Technological advancements: Biotechnology advancements are enabling the development of biosimilars that are highly similar to their originator products
- Regulatory support: Regulatory agencies worldwide are supporting the development and approval of biosimilars
Our biosimilars product portfolio is continuously under development with molecules from pre-clinical to late stages.
Biosimilar products in development
|
Originator |
Disease Indication |
Treatment |
Stage |
Launch Location |
|
Liraglutide (Victoza®) |
Type II Diabetes |
A potent anti-diabetic agent and the first and only human GLP-1 analog. Improves glycemic control in adults with Type II diabetes and reduces the risk of major adverse cardiovascular events in such adults. Also used for the treatment of pediatric patients of 10+ with Type II diabetes. |
Clinical |
TBD |
|
Pertuzumab (Perjeta®) |
HER2-positive metastatic breast cancer |
An anti-neoplastic agent used in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy. Also used in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer with high risk or recurrence. |
Pre-clinical |
TBD |
|
Tocilizumab (Actemra®) |
Rheumatoid arthritis |
A humanized mAb that acts as an immunosuppressant to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to disease-modifying anti-rheumatic drugs. |
Development |
TBD |
Partners we work with
Biomm
Centurion
IDD biotech
Ipca
Start your biosimilars journey
Interested in our biosimilar development pipeline? Reach out to find out more about how Enzene can help deliver trusted and affordable medicines at speed.